Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 564098, 12 pages
Review Article

Biomarkers of Guillain-Barré Syndrome: Some Recent Progress, More Still to Be Explored

1Neuroscience Center, Department of Neurology, The First Hospital of Jilin University, Changchun 130000, China
2Department of Neurology, Heilongjiang Provincial Hospital, Harbin, China
3Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden

Received 28 June 2015; Revised 23 August 2015; Accepted 24 August 2015

Academic Editor: Jagadeesh Bayry

Copyright © 2015 Ying Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Guillain-Barré syndrome (GBS), the axonal subtype of which is mainly triggered by C. jejuni with ganglioside-mimicking lipooligosaccharides (LOS), is an immune-mediated disorder in the peripheral nervous system (PNS) accompanied by the disruption of the blood-nerve barrier (BNB) and the blood-cerebrospinal fluid barrier (B-CSF-B). Biomarkers of GBS have been extensively explored and some of them are proved to assist in the clinical diagnosis and in monitoring disease progression as well as in assessing the efficacy of immunotherapy. Herein, we systemically review the literature on biomarkers of GBS, including infection-/immune-/BNB, B-CSF-B, and PNS damage-associated biomarkers, aiming at providing an overview of GBS biomarkers and guiding further investigations. Furthermore, we point out further directions for studies on GBS biomarkers.